Cilostazol Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysms but Not Atherosclerosis in Apolipoprotein E-Deficient Mice

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 38, Issue 4, 2018, Pages 903-912

  Umebayashi, Ryoko ^a   Uchida, Haruhito A ^a,b   Kakio, Yuki ^a   Subramanian, Venkateswaran ^c,d   Daugherty, Alan ^c,d   Wada, Jun ^a  

^a Endocrinology and Metabolism ^*  (United States)

^b OKAYAMA UNIVERSITY   (Japan)

^c Saha Cardiovascular Research Center   (Japan)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

abdominal aortic aneurysm; angiotensin II; apolipoprotein E; atherosclerosis; cilostazol

Indexed keywords

ANGIOTENSIN II; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E; CILOSTAZOL; CYCLIC AMP DEPENDENT PROTEIN KINASE; MATRIX METALLOPROTEINASE; CELL ADHESION MOLECULE; CYCLIC AMP; CYTOKINE; PHOSPHODIESTERASE III INHIBITOR;

ABDOMINAL AORTA; ABDOMINAL AORTIC ANEURYSM; ANGIOTENSIN II INDUCED ABDOMINAL AORTIC ANEURYSM; ANTIINFLAMMATORY ACTIVITY; AORTIC ATHEROSCLEROSIS; AORTIC ENDOTHELIAL CELL; AORTIC MEDIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CELL INFILTRATION; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME ACTIVATION; GENE EXPRESSION; LIMIT OF QUANTITATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULSE RATE; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; APOLIPOPROTEIN E KNOCKOUT MOUSE; ATHEROSCLEROSIS; CELL CULTURE; CHEMICALLY INDUCED; DISEASE MODEL; ENDOTHELIUM CELL; LESIONS AND DEFECTS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; ATHEROSCLEROSIS; CELL ADHESION MOLECULES; CELLS, CULTURED; CILOSTAZOL; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOKINES; DILATATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; MALE; MICE, KNOCKOUT, APOE; PHOSPHODIESTERASE 3 INHIBITORS; SIGNAL TRANSDUCTION;

EID: 85044372486     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.309707     Document Type: Article

References (72)

1. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet. 2005;365:1577-1589. doi: 10.1016/S0140-6736(05)66459-8.
2. Choke E, Cockerill G, Wilson WR, Sayed S, Dawson J, Loftus I, Thompson MM. A review of biological factors implicated in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg. 2005;30:227-244. doi: 10.1016/j.ejvs.2005.03.009.
3. Takagi H, Yamamoto H, Iwata K, Goto S, Umemoto T; ALICE (All-Literature Investigation of Cardiovascular Evidence) Group. Effects of statin therapy on abdominal aortic aneurysm growth: a meta-analysis and meta-regression of observational comparative studies. Eur J Vasc Endovasc Surg. 2012;44:287-292. doi: 10.1016/j.ejvs.2012.06.021.
4. Sweeting MJ, Thompson SG, Brown LC, Powell JT; RESCAN Collaborators. Meta-analysis of individual patient data to examine factors affecting growth and rupture of small abdominal aortic aneurysms. Br J Surg. 2012;99:655-665. doi: 10.1002/bjs.8707.
5. Thompson SG, Brown LC, Sweeting MJ, Bown MJ, Kim LG, Glover MJ, Buxton MJ, Powell JT. Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. Health Technol Assess. 2013;17:1-118. doi: 10.3310/hta17410.
6. Kuivaniemi H, Ryer EJ, Elmore JR, Tromp G. Understanding the pathogenesis of abdominal aortic aneurysms. Expert Rev Cardiovasc Ther. 2015;13:975-987. doi: 10.1586/14779072.2015.1074861.
7. Saraff K, Babamusta F, Cassis LA, Daugherty A. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:1621-1626. doi: 10.1161/01.ATV.0000085631.76095.64.
8. Koch AE, Haines GK, Rizzo RJ, Radosevich JA, Pope RM, Robinson PG, Pearce WH. Human abdominal aortic aneurysms. Immunophenotypic analysis suggesting an immune-mediated response. Am J Pathol. 1990;137:1199-1213.
9. Juvonen J, Surcel HM, Satta J, Teppo AM, Bloigu A, Syrjälä H, Airaksinen J, Leinonen M, Saikku P, Juvonen T. Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1997;17:2843-2847.
10. Rohde LE, Arroyo LH, Rifai N, Creager MA, Libby P, Ridker PM, Lee RT. Plasma concentrations of interleukin-6 and abdominal aortic diameter among subjects without aortic dilatation. Arterioscler Thromb Vasc Biol. 1999;19:1695-1699.
11. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24:429-434. doi: 10.1161/01. ATV.0000118013.72016.ea.
12. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605-1612. doi: 10.1172/JCI7818.
13. Bruemmer D, Daugherty A, Lu H, Rateri DL. Relevance of angiotensin II-induced aortic pathologies in mice to human aortic aneurysms. Ann N Y Acad Sci. 2011;1245:7-10. doi: 10.1111/j.1749-6632.2011.06332.x.
14. Gitlin JM, Trivedi DB, Langenbach R, Loftin CD. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res. 2007;73:227-236. doi: 10.1016/j. cardiores.2006.10.015.
15. Wang M, Lee E, Song W, Ricciotti E, Rader DJ, Lawson JA, Puré E, FitzGerald GA. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. Circulation. 2008;117:1302-1309. doi: 10.1161/ CIRCULATIONAHA.107.731398.
16. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, Fishbein MC, Blaschke F, Kintscher U, Graf K, Law RE, Hsueh WA. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest. 2003;112:1318-1331. doi: 10.1172/JCI18141.
17. Ishibashi M, Egashira K, Zhao Q, Hiasa K, Ohtani K, Ihara Y, Charo IF, Kura S, Tsuzuki T, Takeshita A, Sunagawa K. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol. 2004;24:e174-e178. doi: 10.1161/01.ATV.0000143384.69170.2d.
18. Usui F, Shirasuna K, Kimura H, Tatsumi K, Kawashima A, Karasawa T, Yoshimura K, Aoki H, Tsutsui H, Noda T, Sagara J, Taniguchi S, Takahashi M. Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35:127-136. doi: 10.1161/ATVBAHA.114.303763.
19. Obama T, Tsuji T, Kobayashi T, Fukuda Y, Takayanagi T, Taro Y, Kawai T, Forrester SJ, Elliott KJ, Choi E, Daugherty A, Rizzo V, Eguchi S. Epidermal growth factor receptor inhibitor protects against abdominal aortic aneurysm in a mouse model. Clin Sci (Lond). 2015;128:559-565. doi: 10.1042/CS20140696.
20. Takayanagi T, Crawford KJ, Kobayashi T, Obama T, Tsuji T, Elliott KJ, Hashimoto T, Rizzo V, Eguchi S. Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase. Clin Sci (Lond). 2014;126:785-794. doi: 10.1042/ CS20130660.
21. Netherton SJ, Maurice DH. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol. 2005;67:263-272. doi: 10.1124/mol.104.004853.
22. Cheng J, Grande JP. Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease. Exp Biol Med (Maywood). 2007;232:38-51.
23. Matsumoto T, Kobayashi T, Kamata K. Phosphodiesterases in the vascular system. J Smooth Muscle Res. 2003;39:67-86.
24. Weintraub WS. The vascular effects of cilostazol. Can J Cardiol. 2006;22(suppl B):56b-60b.
25. Schrör K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002;4(suppl 2):S14-S19.
26. Kim JE, Sung JY, Woo CH, Kang YJ, Lee KY, Kim HS, Kwun WH, Choi HC. Cilostazol inhibits vascular smooth muscle cell proliferation and reactive oxygen species production through activation of AMP-activated protein kinase induced by heme oxygenase-1. Korean J Physiol Pharmacol. 2011;15:203-210. doi: 10.4196/kjpp.2011.15.4.203.
27. Gao L, Wang F, Wang B, Gong B, Zhang J, Zhang X, Zhao J. Cilostazol protects diabetic rats from vascular inflammation via nuclear factorkappa B-dependent down-regulation of vascular cell adhesion molecule-1 expression. J Pharmacol Exp Ther. 2006;318:53-58. doi: 10.1124/ jpet.106.101444.
28. Tsai CS, Lin FY, Chen YH, Yang TL, Wang HJ, Huang GS, Lin CY, Tsai YT, Lin SJ, Li CY. Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. J Cell Biochem. 2008;103:54-66. doi: 10.1002/jcb.21388.
29. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation. 2004;109:1022-1028. doi: 10.1161/01.CIR.0000117403.64398.53.
30. Robinet P, Milewicz DM, Cassis LA, Leeper NJ, Lu HS, Smith JD. Consideration of sex differences in design andreporting of experimental arterial pathology studies-statement from ATVB council. Arterioscler Thromb Vasc Biol. 2018;38:292-303. doi: 10.1161/ATVBAHA.117.309524.
31. Lu H, Howatt DA, Balakrishnan A, Moorleghen JJ, Rateri DL, Cassis LA, Daugherty A. Subcutaneous angiotensin II infusion using osmotic pumps induces aortic aneurysms in mice. J Vis Exp. 2015;103:e53191. doi: 10.3791/53191.
32. Daugherty A, Rateri D, Hong L, Balakrishnan A. Measuring blood pressure in mice using volume pressure recording, a tail-cuff method. J Vis Exp. 2009;27:1291. doi: 10.3791/1291.
33. Daugherty A, Tall AR, Daemen MJAP, Falk E, Fisher EA, García-Cardeña G, Lusis AJ, Owens AP III, Rosenfeld ME, Virmani R; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; and Council on Basic Cardiovascular Sciences. Recommendation on design, execution, and reporting of animal atherosclerosis studies: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2017;37:e131-e157. doi: 10.1161/ATV.0000000000000062.
34. Uchida HA, Sugiyama H, Takiue K, Kikumoto Y, Inoue T, Makino H. Development of angiotensin II-induced abdominal aortic aneurysms is independent of catalase in mice. J Cardiovasc Pharmacol. 2011;58:633-638. doi: 10.1097/FJC.0b013e3182317196.
35. Uchida HA, Poduri A, Subramanian V, Cassis LA, Daugherty A. Urokinase-type plasminogen activator deficiency in bone marrow-derived cells augments rupture of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2011;31:2845-2852. doi: 10.1161/ ATVBAHA.111.234997.
36. Uchida HA, Kristo F, Rateri DL, Lu H, Charnigo R, Cassis LA, Daugherty A. Total lymphocyte deficiency attenuates AngII-induced atherosclerosis in males but not abdominal aortic aneurysms in apoE deficient mice. Atherosclerosis. 2010;211:399-403. doi: 10.1016/j. atherosclerosis.2010.02.034.
37. Daugherty A, Whitman SC. Quantification of atherosclerosis in mice. Methods Mol Biol. 2003;209:293-309.
38. Howatt DA, Balakrishnan A, Moorleghen JJ, Muniappan L, Rateri DL, Uchida HA, Takano J, Saido TC, Chishti AH, Baud L, Subramanian V. Leukocyte calpain deficiency reduces angiotensin II-induced inflammation and atherosclerosis but not abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol. 2016;36:835-845. doi: 10.1161/ ATVBAHA.116.307285.
39. Subramanian V, Moorleghen JJ, Balakrishnan A, Howatt DA, Chishti AH, Uchida HA. Calpain-2 compensation promotes angiotensin II-induced ascending and abdominal aortic aneurysms in calpain-1 deficient mice. PLoS One. 2013;8:e72214. doi: 10.1371/journal.pone.0072214.
40. Lu H, Rateri DL, Daugherty A. Immunostaining of mouse atherosclerotic lesions. Methods Mol Med. 2007;139:77-94.
41. Miyoshi T, Matsumoto AH, Shi W. Paradoxical increase in LDL oxidation by endothelial cells from an atherosclerosis-resistant mouse strain. Atherosclerosis. 2007;192:259-265. doi: 10.1016/j. atherosclerosis.2006.07.016.
42. Shi W, Haberland ME, Jien ML, Shih DM, Lusis AJ. Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice. Circulation. 2000;102:75-81.
43. Lorenowicz MJ, Fernandez-Borja M, Hordijk PL. cAMP signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol. 2007;27:1014-1022. doi: 10.1161/ATVBAHA.106.132282.
44. Nishio Y, Kashiwagi A, Takahara N, Hidaka H, Kikkawa R. Cilostazol, a cAMP phosphodiesterase inhibitor, attenuates the production of monocyte chemoattractant protein-1 in response to tumor necrosis factor-alpha in vascular endothelial cells. Horm Metab Res. 1997;29:491-495. doi: 10.1055/s-2007-979086.
45. Kim KY, Shin HK, Choi JM, Hong KW. Inhibition of lipopolysaccharideinduced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther. 2002;300:709-715.
46. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kurabayashi M, Kasayama S. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence. Atherosclerosis. 2001;158:121-128.
47. Zhang Q, Huang JH, Xia RP, Duan XH, Jiang YB, Jiang Q, Sun WJ. Suppression of experimental abdominal aortic aneurysm in a rat model by the phosphodiesterase 3 inhibitor cilostazol. J Surg Res. 2011;167:e385-e393. doi: 10.1016/j.jss.2011.01.017.
48. Gantner F, Kupferschmidt R, Schudt C, Wendel A, Hatzelmann A. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors. Br J Pharmacol. 1997;121:221-231. doi: 10.1038/sj.bjp.0701124.
49. Nakamura T, Houchi H, Minami A, Sakamoto S, Tsuchiya K, Niwa Y, Minakuchi K, Nakaya Y. Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci. 2001;69:1709-1715.
50. Petersen E, Gineitis A, Wågberg F, Angquist KA. Activity of matrix metalloproteinase-2 and-9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg. 2000;20:457-461. doi: 10.1053/ejvs.2000.1211.
51. Aziz F, Kuivaniemi H. Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm. Ann Vasc Surg. 2007;21:392-401. doi: 10.1016/j.avsg.2006.11.001.
52. Kadoglou NP, Liapis CD. Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin. 2004;20:419-432. doi: 10.1185/030079904125003143.
53. Eagleton MJ, Ballard N, Lynch E, Srivastava SD, Upchurch GR Jr, Stanley JC. Early increased MT1-MMP expression and late MMP-2 and MMP-9 activity during angiotensin II induced aneurysm formation. J Surg Res. 2006;135:345-351. doi: 10.1016/j.jss.2006.03.026.
54. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649. doi: 10.1172/JCI8931.
55. Xiong W, Knispel R, Mactaggart J, Baxter BT. Effects of tissue inhibitor of metalloproteinase 2 deficiency on aneurysm formation. J Vasc Surg. 2006;44:1061-1066. doi: 10.1016/j.jvs.2006.06.036.
56. da Cunha V, Tham DM, Martin-McNulty B, Deng G, Ho JJ, Wilson DW, Rutledge JC, Vergona R, Sullivan ME, Wang YX. Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. Atherosclerosis. 2005;178:9-17. doi: 10.1016/j.atherosclerosis.2004.08.023.
57. Thatcher SE, Zhang X, Woody S, Wang Y, Alsiraj Y, Charnigo R, Daugherty A, Cassis LA. Exogenous 17-β estradiol administration blunts progression of established angiotensin II-induced abdominal aortic aneurysms in female ovariectomized mice. Biol Sex Differ. 2015;6:12. doi: 10.1186/s13293-015-0030-1.
58. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther. 2005;313:502-509. doi: 10.1124/jpet.104.079780.
59. Takase H, Hashimoto A, Okutsu R, Hirose Y, Ito H, Imaizumi T, Miyakoda G, Mori T. Anti-atherosclerotic effect of cilostazol in apolipoprotein-E knockout mice. Arzneimittelforschung. 2007;57:185-191. doi: 10.1055/s-0031-1296604.
60. Daugherty A, Cassis LA, Lu H. Complex pathologies of angiotensin II-induced abdominal aortic aneurysms. J Zhejiang Univ Sci B. 2011;12:624-628. doi: 10.1631/jzus.B1101002.
61. Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT; UK Small Aneurysm Trial Participants. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004;110:16-21. doi: 10.1161/01.CIR.0000133279.07468.9F.
62. Lindholt JS, Heegaard NH, Vammen S, Fasting H, Henneberg EW, Heickendorff L. Smoking, but not lipids, lipoprotein(a) and antibodies against oxidised LDL, is correlated to the expansion of abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2001;21:51-56. doi: 10.1053/ ejvs.2000.1262.
63. Liu J, Lu H, Howatt DA, Balakrishnan A, Moorleghen JJ, Sorci-Thomas M, Cassis LA, Daugherty A. Associations of ApoAI and ApoB-containing lipoproteins with AngII-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol. 2015;35:1826-1834. doi: 10.1161/ ATVBAHA.115.305482.
64. Zhang Y, Naggar JC, Welzig CM, Beasley D, Moulton KS, Park HJ, Galper JB. Simvastatin inhibits angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-knockout mice: possible role of ERK. Arterioscler Thromb Vasc Biol. 2009;29:1764-1771. doi: 10.1161/ ATVBAHA.109.192609.
65. Yoshihara T, Shimada K, Fukao K, Sai E, Sato-Okabayashi Y, Matsumori R, Shiozawa T, Alshahi H, Miyazaki T, Tada N, Daida H. Omega 3 polyunsaturated fatty acids suppress the development of aortic aneurysms through the inhibition of macrophage-mediated inflammation. Circ J. 2015;79:1470-1478. doi: 10.1253/circj.CJ-14-0471.
66. Weiss N, Rodionov RN, Mahlmann A. Medical management of abdominal aortic aneurysms. Vasa. 2014;43:415-421. doi: 10.1024/0301-1526/ a000388.
67. Boucek RJ, Gunja-Smith Z, Noble NL, Simpson CF. Modulation by propranolol of the lysyl cross-links in aortic elastin and collagen of the aneurysm-prone turkey. Biochem Pharmacol. 1983;32:275-280.
68. Brophy CM, Tilson JE, Tilson MD. Propranolol stimulates the crosslinking of matrix components in skin from the aneurysm-prone blotchy mouse. J Surg Res. 1989;46:330-332.
69. Touat Z, Ollivier V, Dai J, Huisse MG, Bezeaud A, Sebbag U, Palombi T, Rossignol P, Meilhac O, Guillin MC, Michel JB. Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution. Am J Pathol. 2006;168:1022-1030. doi: 10.2353/ ajpath.2006.050868.
70. Dai J, Louedec L, Philippe M, Michel JB, Houard X. Effect of blocking platelet activation with AZD6140 on development of abdominal aortic aneurysm in a rat aneurysmal model. J Vasc Surg. 2009;49:719-727. doi: 10.1016/j.jvs.2008.09.057.
71. Lindholt JS, Björck M, Michel JB. Anti-platelet treatment of middle-sized abdominal aortic aneurysms. Curr Vasc Pharmacol. 2013;11:305-313.
72. Owens AP III, Edwards TL, Antoniak S, Geddings JE, Jahangir E, Wei WQ, Denny JC, Boulaftali Y, Bergmeier W, Daugherty A, Sampson UKA, Mackman N. Platelet inhibitors reduce rupture in a mouse model of established abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35:2032-2041. doi: 10.1161/ATVBAHA.115.305537.